The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | A single-center experience of treating PNH using complement inhibitors in Czechia
Jaroslav Čermák, MD, Institute of Hematology and Blood Transfusion (ÚHKT), Prague, Czechia, comments on the success of treating patients with paroxysmal nocturnal hemoglobinuria (PNH) using complement inhibitors at his center in Czechia. Prof. Čermák notes that the center has treated 21 patients with proximal or terminal complement inhibitors, achieving a total response rate of 84% and a 10-year survival rate of almost 100%. This is significantly higher than the survival rate of patients not on complement inhibitors. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, we are treating patients with terminal inhibitors since 2011. And altogether we have now 21 patients treated with complement inhibitors. This is the highest number in the country because we have altogether 35 patients treated with inhibitors, from the total amount of 85 patients in the country. So we have started with C5 inhibitors for a long time and then we have a possibility, we have switched to patients who were indicated for proximal inhibitors...
You know, we are treating patients with terminal inhibitors since 2011. And altogether we have now 21 patients treated with complement inhibitors. This is the highest number in the country because we have altogether 35 patients treated with inhibitors, from the total amount of 85 patients in the country. So we have started with C5 inhibitors for a long time and then we have a possibility, we have switched to patients who were indicated for proximal inhibitors. So nowadays we have about six or seven patients on proximal inhibitors and the rest of the patients are on terminal inhibitors and I think we were quite successful because the treatment response to C5 inhibitors was about 63% or 64% of patients. The remaining patients were switched to C3 inhibitors and they were successful in 100% of these patients. That means that the total response of patients is about 84% to complement inhibitors. That seems to me to be very good. And what is really good to me is just to have survival. Survival for 10 years is almost 100%. So it’s great to be compared with the survival of the patients who are not on complement inhibitors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
